Intravesical therapy, often called bladder instillations, is a primary treatment for early stage bladder cancer in the UK. This involves putting liquid medication directly into the bladder through a catheter to target cancer cells in the lining. It is highly effective for non muscle invasive bladder cancer, helping to prevent the disease from returning or progressing into the deeper muscle layers.
Bladder instillations are a specialised form of treatment where drugs are delivered directly to the site of the cancer. Unlike systemic chemotherapy which affects the whole body, intravesical therapy focuses its action on the bladder lining. This approach is particularly useful for patients with non muscle invasive bladder cancer (NMIBC), which is cancer that has not yet grown into the thick muscle wall of the bladder. In this article, you will learn about how these instillations work, the different types of medication used, and what to expect during a course of treatment in the UK.
What We will cover in this Article
- How intravesical therapy targets cancer cells locally
- The difference between chemotherapy and immunotherapy instillations
- The role of TURBT surgery before starting bladder instillations
- Common causes and environmental triggers of bladder cancer
- Differentiation between induction and maintenance therapy phases
- Side effects and safety precautions during treatment
- UK clinical guidelines for monitoring and follow up care
How Intravesical Therapy Works
Intravesical therapy involves the administration of liquid medication into the bladder via a thin, flexible tube called a catheter. Once the medicine is inside, it remains there for a set period, usually one to two hours, allowing it to have direct contact with the bladder lining. This direct contact is intended to destroy any remaining cancer cells and prevent new tumours from forming.
This method is highly effective because it delivers a concentrated dose of medication exactly where it is needed while minimising side effects elsewhere in the body. It is typically used after a patient has undergone a transurethral resection of a bladder tumour (TURBT) to ensure that microscopic cells not visible during surgery are targeted. According to the British Association of Urological Surgeons (BAUS), this treatment is a standard approach for intermediate and high risk non muscle invasive cancers.
- Direct Delivery: Medication reaches the bladder lining directly.
- Catheterisation: A sterile procedure performed in an outpatient clinic.
- Retention Time: Patients are often asked to hold the fluid for 60 to 120 minutes.
- Local Action: Reduces the risk of systemic side effects like hair loss or nausea.
Types of Bladder Instillations (BCG vs. Chemotherapy)
There are two main categories of intravesical therapy used in the UK: chemotherapy and immunotherapy. Intravesical chemotherapy, such as Mitomycin C, uses cytotoxic drugs to kill cancer cells directly. This is often given as a single dose immediately after surgery or as a six week course for intermediate risk patients.
BCG (Bacillus Calmette Guérin) is an immunotherapy made from a weakened strain of bacteria. Instead of killing cells directly, it stimulates the body’s own immune system to attack the cancer. NICE guidelines (National Institute for Health and Care Excellence, updated 2024) recommend BCG for high risk non muscle invasive bladder cancer as it is superior at preventing the cancer from becoming invasive.
(Source: https://www.nice.org.uk/guidance/ng2).
| Feature | Intravesical Chemotherapy (e.g., Mitomycin C) | Intravesical Immunotherapy (BCG) |
| Primary Goal | Kill remaining cancer cells directly | Stimulate immune system to kill cells |
| Common Use | Low or intermediate risk NMIBC | High risk NMIBC or CIS |
| Timing | Often given within 24 hours of surgery | Started at least 2 weeks after surgery |
| Mechanism | Cytotoxic (cell killing) | Biological response modifier |
Causes of Early Bladder Cancer
The development of early bladder cancer is primarily linked to the accumulation of carcinogens in the urine. When the body processes certain chemicals, the kidneys filter them into the urine, which then sits in the bladder. This prolonged contact can damage the DNA of the cells lining the bladder (the urothelium), leading to cancerous mutations.
Smoking is the leading cause of bladder cancer in the UK, responsible for nearly 50% of all cases. Research conducted by Cancer Research UK (published 2023) highlights that tobacco contains over 60 known carcinogens that are excreted in the urine (Source: https://www.cancerresearchuk.org/about-cancer/bladder-cancer). Other factors include chronic bladder irritation from stones or long term catheter use.
- Tobacco Smoke: The most significant preventable risk factor.
- Chemical Exposure: Processing of industrial chemicals.
- Age: Risk increases significantly in those over the age of 60.
- Gender: More common in men, though rates in women are rising.
Common Triggers and Risk Factors
Environmental and occupational triggers are significant in the UK clinical landscape. Historically, workers in the rubber, dye, and textile industries were at high risk due to exposure to aromatic amines. Although many of these chemicals are now banned, the long latency period of bladder cancer means cases may still appear decades after exposure.
Modern triggers include long term exposure to diesel engine exhaust and certain solvents used in professional painting or printing. Dehydration can also be a factor, as drinking less water leads to more concentrated urine, increasing the ‘contact time’ that toxins have with the bladder wall.
- Industrial Dyes: Previous employment in dye or textile manufacturing.
- Diesel Fumes: Relevant for transport and construction workers.
- Pelvic Radiotherapy: Previous treatment for other cancers.
- Chronic Infections: Long term untreated urinary tract infections.
Differentiation: Induction vs. Maintenance Therapy
Treatment is often divided into two distinct phases. The induction phase is the initial course, typically consisting of one instillation per week for six consecutive weeks. This phase aims to clear any remaining cancer and trigger a strong initial response from the immune system or the cytotoxic drugs.
Maintenance therapy follows the induction phase for patients at higher risk of recurrence. This involves less frequent instillations, often given in three week blocks every few months for one to three years. The goal of maintenance is to provide long term protection and reduce the chance of the cancer returning. As stated by Macmillan Cancer Support (2025), maintenance therapy significantly improves the long term success rate of BCG
- Induction: Weekly sessions for 6 weeks to clear visible disease.
- Maintenance: Periodic sessions over 1 to 3 years for high risk cases.
- Monitoring: Regular cystoscopies are performed alongside therapy.
- Adjustment: Schedules may be modified based on patient tolerance.
My final conclusion
Intravesical therapy is a highly effective, targeted treatment for early stage bladder cancer in the UK. By delivering medication directly into the bladder, it maximises the impact on cancer cells while sparing the rest of the body from significant side effects. Whether using chemotherapy or BCG immunotherapy, these instillations are vital for preventing recurrence and avoiding the need for more invasive surgery. If you experience severe, sudden, or worsening symptoms, call 999 immediately.
Is the treatment painful?
The insertion of the catheter may be slightly uncomfortable, but local anaesthetic gel is used to make the process as smooth as possible.
Can I drive home after the session?
Yes, most patients are able to drive themselves to and from their appointments as the treatment does not involve sedation.
What is the ‘6 hour rule’ after BCG?
For six hours after BCG treatment, you must take care when urinating to avoid splashing, as the fluid contains live, weakened bacteria.
Will I lose my hair with this chemotherapy?
No, because the chemotherapy is put directly into the bladder and not the bloodstream, it does not cause hair loss or severe nausea.
How soon after surgery can I start?
A single dose of chemo is often given immediately, but a full course usually starts two to four weeks after surgery to allow the bladder to heal.
What are the common side effects?
The most common side effects include bladder irritation, a frequent need to urinate, and a mild burning sensation during urination.
What if I cannot hold the fluid for two hours?
Do not worry; even holding the medication for a shorter period can still be beneficial, and your clinical team can provide advice if this is difficult.
Authority Snapshot
Dr. Rebecca Fernandez is a UK trained physician with an MBBS and experience in general surgery, cardiology, internal medicine, gynecology, intensive care, and emergency medicine. She has managed critically ill patients, stabilised acute trauma cases, and provided comprehensive inpatient and outpatient care. In psychiatry, Dr. Fernandez has worked with psychotic, mood, anxiety, and substance use disorders, applying evidence based approaches such as CBT, ACT, and mindfulness based therapies. Her skills span patient assessment, treatment planning, and the integration of digital health solutions to support mental well being. This article provides safe, general information based on UK clinical standards and is intended for public education.
